Stock listing

Xbiotech Inc.

Selected listing: A14QF1 · LS · EUR · DE

Xbiotech Inc. (Lang & Schwarz: A14QF1), Health Technology. Latest release Jun 15, 2026: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug…

A14QF1:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A14QF1
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Xbiotech Inc.

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

June 17, 2024

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

January 3, 2024

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

September 25, 2023

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

August 29, 2023

All Xbiotech Inc. news →

Research Xbiotech Inc.

Xbiotech Inc. company profile

View the public company page for Xbiotech Inc. on 6ix.

Xbiotech Inc. news

Read company news and market updates connected to Xbiotech Inc..

Xbiotech Inc. investor events

Find investor webinars, events, and replay context for Xbiotech Inc..